Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effect of Omicron on the prevalence of COVID-19 in international travelers at the Mexico city international airport. December 16th, 2021 to January 31st, 2022

Gustavo Olaiz-Fernández a, Félix Jesús Vícuna de Anda a, Jorge-Baruch Díaz-Ramírez b, German E. Fajardo Dolci c, Patricia Bautista-Carbalaj d, Antonio Humberto Angel-Ambrocio d, Miguel Leonardo García-León d, Elena Gómez Peña a, Jorge Alejandro Camacho Morales c, Rosa María Wong-Chew d,∗

a Center for Research in Policies, Population and Health, Faculty of Medicine Universidad Nacional Autónoma de México (UNAM), Edificio CIPPS, Piso 2, Cto. Centro Cultural Universitario S/N, Coyoacán, 04510, Ciudad de México, Mexico
b Traveler’s Preventive Care Clinic, Facultad de Medicina UNAM, Aeropuerto Internacional de la Ciudad de México “Benito Juárez”, Terminal 2, Venustiano Carranza, 15626, Ciudad de México, Mexico
c UNAM, Cto. Escolar 411A, Copilco Universidad, Coyoacán, 04510, Ciudad de México, Mexico
d División de Investigación, Laboratorio de Investigación en enfermedades infecciosas, Facultad de Medicina UNAM, Cto. Escolar S/N, Copilco el Alto, Coyoacán, 04510, Ciudad de México, Mexico
*e Department of Biomedical Informatics, Faculty of Medicine UNAM, Cto. Escolar S/N, Copilco el Alto, Coyoacán, 04510, Ciudad de México, Mexico

ARTICLE INFO

Keywords:
Travel medicine
Travel-related illness
COVID-19 testing
Asymptomatic infections
Epidemiologic factors
Pandemics

ABSTRACT

Introduction: SARS-CoV-2 continues to have a high rate of contagion worldwide. The new variant of concern, Omicron, has mutations that decrease the effectiveness of vaccines and evade antibodies from previous infections resulting in a fourth wave of the pandemic. It was identified in Mexico in December 2021.

Methods: The Traveler’s Preventive Care Clinic from the Faculty of Medicine UNAM at Mexico City International Airport has performed rapid antigen and PCR SARS CoV2 tests since January 2021 to comply with the new travel requirements. Demographic and clinical characteristics were collected from each passenger and the fourth wave of the pandemic in Mexico mainly caused by Omicron was analyzed in the travelers.

Results: A total of 5176 travelers attended the clinic between the second half of December 2021 and January 2022. Ten percent of all the tests performed were positive (13% of PCR and 9.3% of antigens, p = 0.001). Most of the SARS CoV2 positive cases were asymptomatic (78%), with a ratio of 3.5:1 over the symptomatic. By age groups, this ratio was higher for those under 20 years old (8.7:1).

Discussion: This study shows the rapid escalation of positivity that occurred in Mexico, detected in travelers, from the second half of December 2020 and throughout the month of January 2021. The incidence of COVID-19 was extremely high in travelers who were mostly asymptomatic for the period under study.

1. Introduction

Acute respiratory diseases in travelers are common, and can be characterized among them by age, sex, trip duration and type of travel to understand their impact and risk factors. These diseases have been observed in 7.8%–20% of the international travel population [1]. As globalization accelerates the mobility of infectious diseases far beyond national boundaries, many variants of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have emerged.

On November 26th, 2021, two years after the first reported case, the World Health Organization (WHO) alerted about a new SARS-CoV-2 variant of concern: Omicron. On December 3rd, the first case of

Abbreviations: WHO, World Health Organization; SARS CoV2, Severe Acute Respiratory Syndrome Coronavirus 2; CAPV, Traveler’s preventive care clinic (acronym in Spanish, Clínica de atención preventiva del viajero); SCU, Sample collection Unit; AICM, Mexico city international airport (acronym in Spanish, Aeropuerto Internacional de la Ciudad de México); UNAM, Universidad Nacional Autónoma de México.

* Corresponding author.

E-mail address: rmwong@unam.mx (R.M. Wong-Chew).

https://doi.org/10.1016/j.tmaid.2022.102361

Received 21 February 2022; Received in revised form 27 April 2022; Accepted 22 May 2022

Available online 29 May 2022

1477-8939/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Omicron in Mexico was identified and reported [2].

The new Omicron variant (lineage B.1.1.529) has shown that a large number of mutations in the S protein decreases the effectiveness of vaccines (although it protects against severe disease and death) and evades antibodies generated by previous infections (reinfections), causing a new wave of the pandemic. In a couple of months, it became the predominant variant in the world [3].

Following the identification of this variant, governments around the world took again steps to minimize its impact (entry restrictions that include border closures, bans by nationality, suspension of international flights; and conditions for entry, for example, medical requirements) [4, 5]. However, Omicron has a much higher rate of infection, transmission, and asymptomatic carriers; this high prevalence of asymptomatic infection is likely a major factor in the rapid and global widespread, even among populations with prior high rates of COVID. It is worth mentioning that these asymptomatic carriers have high viral titers; suggesting that it is an important factor in the rapid global spread [6].

Recent studies have estimated that Omicron has double the reproduction number of the Delta variant, and that the absence of symptoms may not imply the absence of harm. Asymptomatic carriers represent a significant part in their early identification to prevent transmission [7], since the viral load in these asymptomatic patients is comparable to that of symptomatic ones [8].

Although effectiveness of epidemiological containment and mitigation measures have been well assessed in general population, few studies have been done to evaluate entry restrictions and conditions at international airports. Sociodemographic, migratory and health characteristics of COVID-19 travelers screened at the airports may play an important role to inform policy-making efforts in the context of international travel and health security for future epidemics [9].

The present study documents the prevalence of COVID-19 in international travelers at the Mexico City International Airport during the 2021–2022 holiday season and shows the effect of a new SARS-CoV2 variant during the fourth wave in this specific population. Social, migratory and health characteristics of the cases were assessed to find a possible association with COVID-19 test positivity.

2. Methodology

The Faculty of Medicine of Universidad Nacional Autónoma de México (UNAM) has managed for 10 years the Traveler’s Preventive Care Clinic (CAPV, for its acronym in Spanish), which is located in Terminal 2 of the country’s main airport: Mexico City International Airport (AICM, for its acronym in Spanish).

The clinic offers multiple high quality services to travelers at the AICM. As of the end of January 2021, the Clinic installed the Sample Collection Unit (SCU) in the vicinity of the AICM.

The traveler’s flux is constant and increases along the holiday season, according to the regulations imposed by each country of destination, the SCU performs rapid tests of Antigen (Roche, Seegene and Landsteiner brand) of lateral flow. As a rule, these tests are currently requested within less than 24 h before boarding. In other cases, tests such as PCR (Reverse transcriptase polymerase chain reaction test) are requested, (Allplex 2019-nCoV Assay brand, Seegene) which is a multiple real-time PCR assay for the simultaneous detection of 4 genes; the assay is designed to detect the RdRP, S and N genes specific for SARS-CoV-2 and the E gene for all sarbecoviruses, including SARS-CoV-2.

All travelers are given a questionnaire to inquire their demographic and clinical characteristics, travel itinerary and symptoms suggestive of COVID-19. To obtain a travel certificate, a full name, sex, nationality, age and date of birth are required; in addition to the questionnaire and signs and symptoms that have been present in the last seven (7) days such as headache, cough, shortness of breath, runny nose, muscle pain, joint pain, fatigue, sore throat, diarrhea, nausea, vomiting; also the presence of some diseases or comorbidities such as cancer, systemic arterial hypertension, autoimmune diseases, pregnancy, kidney or liver failure and finally their weight and height.

All travelers are informed of their results personally; those who are positive are given guidance and basic isolation information, and a doctor from the CAPV contacts them to carry out personalized follow-up of their case. The time to perform a new test is suggested, and they are also given a discharge medical certificate by the CAPV at the end of the disease. The information of each traveler is stored in a secure database at the CAPV, and the cases are reported to the health authority.

For the present analysis, the database was selected between December 16th, 2021 and January 31st, 2022, which corresponds to the fourth epidemic peak in our country when Omicron was prevalent. Travelers’ personal information was removed, and only statistical data was considered. The analysis was performed with the SPSS program (Statistical Package for the Social Sciences) version 28.0.

3. Results

Information was obtained from 5176 travelers who attended the SCU in the indicated period. This service is offered to anyone who comes to the facilities and meets the diagnostic requirements of each country to which travelers go. In general, the requirements are rapid antigen test for travelers to North America, PCR for travelers to Europe and mixed for other destinations. According to this distribution and given that the United States of America (USA) is the main destination for travelers leaving the AICM, most of the travelers require rapid antigen tests (4273 or 82.6%) and in a lower proportion PCR (903 for 17.4%). The positivity for antigens was 9.3% and 13% for PCR (p = 0.001) (Table 1). In contrast, the positivity observed during 2021, from January to March was 1%, April to June was 0.27%–0.44%, July and August was 4%, September was 1%, October and November 0.89% and 0.39% respectively, December was 2.78% and January 14.9%. July and August correspond to the Delta wave and December and January to the Omicron wave in Mexico.

The characteristics of the travelers are presented in Table 2, where the number of under 20 years of age represents a proportion close to a fifth (16.5%), since this season includes the winter vacation period in Mexico. The largest proportion of travelers is between 20 and 59 years of age (73.7%) and the population over 60 years represents a smaller proportion (9.8%). The distribution by sex shows no differences in the proportion of men and women. A little more than half of the travelers that were studied are Mexicans (57.3%), followed in frequency by those born in the United States (29.7%) and in the third group are Europeans (5.3%).

Regarding the characteristics of the trip (Table 2), most travelers reported tourism as the reason for their trip (48.9%), followed by emigration/returning home (37.2%) and to a lesser extent, business, and students. North America was the most frequent travel site followed by Europe.

Due to the low prevalence of symptoms, they were grouped for the analysis and the result is shown in Table 3. Most of the travelers are free of symptoms (95.0%). Of those who presented symptoms, they presented cough, headache, or fever. These three symptoms represent the combinations observed in Table 3. During the Omicron wave (December 16th to January 31st) 9.9% of travelers were positive; 2 times the Delta wave and 10 times the rest of the pandemic. Most of the positive cases

Table 1

| Test type | ANTIGEN | PCR | Total |
|-----------|---------|-----|-------|
| NEGATIVE n (%) | 3876 (90.7) | 786 (87.0) | 4662 (90.1) |
| POSITIVE n (%)  | 397 (9.3)   | 117 (13.0)  | 514 (9.9) |

Chi squared dist. p = 0.001.
3

Table 2
Demographic characteristics of the travelers attending the CAPV for SARS CoV2 tests. December 16th, 2021 to January 31st, 2022.

| Number | Percentage |
|--------|------------|
| AGE GROUP |          |
| Less than 20 | 856 | 16.5 |
| 20 to 29 | 1022 | 19.7 |
| 30 to 39 | 1144 | 22.1 |
| 40 to 49 | 854 | 16.5 |
| 50 to 59 | 795 | 15.4 |
| 60 and more | 505 | 9.8 |
| Total | 2332 | 100.0 |
| GENDER |          |
| FEMALE | 2509 | 48.5 |
| MALE | 2667 | 51.1 |
| Total | 2332 | 100.0 |
| NATIONALITY | | |
| Mexico | 2965 | 57.3 |
| EEUU | 1539 | 29.7 |
| Europe | 276 | 5.3 |
| Rest of America | 263 | 5.1 |
| Another country | 133 | 2.6 |
| Total | 5176 | 100.0 |
| REASON FOR THE TRIP | | |
| EMIGRATION/RETURNING HOME | 1924 | 37.2 |
| STUDIES | 153 | 3.0 |
| TOURISM | 187 | 3.6 |
| OTHER | 2116 | 40.9 |
| Total | 5176 | 100 |
| TRAVELING REGION | | |
| NORTH AMERICA | 3953 | 76.4 |
| EUROPE | 603 | 11.6 |
| OTHER | 620 | 12.0 |
| Total | 2332 | 100.0 |

Table 3
Suggestive symptoms of COVID-19 and test results in travelers attending the CAPV. December 16th, 2021 to January 31st, 2022.

| Number | Percentage |
|--------|------------|
| COVID-19 suggestive symptoms | | |
| None | 4918 | 95.0 |
| One symptom | 168 | 3.2 |
| Two symptoms | 63 | 1.2 |
| Three or more | 27 | 0.5 |
| Total | 2332 | 100.0 |
| RESULTS | | |
| NEGATIVE | 4662 | 90.1 |
| POSITIVE | 514 | 9.9 |
| Total | 2332 | 100.0 |
| Classification according to symptoms | | |
| No case of COVID-19 | 4662 | 90.1 |
| Asymptomatic case | 399 | 7.7 |
| Symptomatic case | 115 | 2.2 |
| Total | 2332 | 100.0 |

were asymptomatic (7.7%), which represents a ratio of 3:5:1 over symptomatic cases, which means that 78% of the cases were asymptomatic.

The proportion of cases of asymptomatic COVID-19 is high from those under 20 years of age to rise slightly up to those over 60 years of age, where it reaches 9.9% of identified cases. The asymptomatic/symptomatic ratio is 8.7:1 for those under 20 years of age (Table 4 and Figure 1).

According to nationality, most of the symptomatic cases correspond to the Mexican population. In the case of asymptomatic, it was lower for Europeans (3.3%) and North Americans (4.9%), and it was similar (10%) for Mexican travelers and the rest of the world.

Travelers who had various reasons for their trip had the highest proportion of cases, both symptomatic and asymptomatic, followed by those who traveled for tourism and for studies. When considering the regions of the trip, those traveling to Europe had the lowest incidence of COVID-19, both asymptomatic and symptomatic.

4. Discussion

Mexico has not adopted restrictions for the air entry of visitors and the return of Mexicans from other countries. It does not request test certificates or vaccination certificates; they only "invite" people who present symptoms associated with the coronavirus to take the corresponding protection and prevention measures. This is closely related to the increase in international arrivals of thousands of international tourists (especially from the United States), due to the lack of entry restrictions and conditions [10–13].

The COVID-19 pandemic has had multiple epidemic peaks due to the appearance and spread of new variants which have maintained the transmission of the SARS-CoV-2 virus [3], both asymptomatic [2] and in clinical cases of varying severity [14–16]. These variants, in general terms, have maintained a similar level of severity, except for the Alpha and Delta variants, which, due to their greater transmission capacity, caused a large burden of morbidity and mortality [17]. On the other hand, some variants had greater infectivity and some the ability to evade the immune system or both [18,19].

The last of the identified variants of concern, Omicron, was detected in Mexico on December 3rd, 2021, and began to spread in the Mexican population. This variant has multiple modifications in relation to the previous variants and is the most contagious of the variants, so its rapid transmission was expected in a population with medium vaccination levels [19–23].

The Omicron variant has also been pointed out as the one that is proportionally transmitted more asymptptomatically [2,6,22] consequently, it is assumed that it would be common to find in the population. In this study it was found that 78% of positive cases are asymptomatic. It should be noted that travelers do not go for tests because they present symptoms but for health requirements at their travel destinations. Mexico had an alarming and increasing number of contagions, but testing was severely restricted. While most of the world continues to shift from entry restrictions to conditions for authorized entry, the last ones including single predeparture testing, quarantine upon arrival with or without discharge testing, reduced quarantine followed by testing, single PCR testing post arrival, or quarantine upon arrival, travelers arriving to Mexico are not required to present negative COVID results, moreover hotels, touristic facilities and restaurants do not have specific mandates in this area; therefore, visitors have no restrictions whatsoever and may spread or be infected almost anywhere [13]. World tourism registered 2020 as the worst year with 74% reduction, mainly because of COVID restrictions [24]. In 2021 world tourism grew only 4% [25]; but in Mexico, that has no restrictions there was a 30.2% increase of international travelers between 2020 and 2021 [26,27].

Mexico, through the General Directorate of Epidemiology has increased their limited capacity to perform COVID testing certifying 185 laboratories and hospitals to perform antigen and/or PCR testing [28]. However, most of them do not comply with guidelines to provide certificates for travelers; on the other hand, there are a number of improvised and not certified tents, modules in hotels, and laboratories that issue certificates that allow travelers to board airplanes to most destinations [29–31].

In Mexico, where very limited number of diagnostic tests are performed, and mainly on people with symptoms, failures in case follow-up and high transmissibility are common [32–35]. And the lack of COVID test requirements for entry contributes even more with the dissemination of the new variants [4,36].

The population that attends the SCU of the CAPV is comprised of international travelers leaving the AICM. This airport is the most important in the number of flights and passengers, even so, we must consider that the population that goes to the SCU is self-selected and includes only international travelers with an itinerary from Mexico City.

Most of the destinations had shifted to preferred medical conditions requirements instead of travel restrictions, all of them regulated by the national governments of the countries involved during the transit and

G. Olait-Fernández et al.

Travel Medicine and Infectious Disease 49 (2022) 102361

December 16th, 2021 to January 31st, 2022.

those who traveled for tourism and for studies. When considering the regions of the trip, those traveling to Europe had the lowest incidence of COVID-19, both asymptomatic and symptomatic.
Travel Medicine and Infectious Disease 49 (2022) 102361

As noted in Table 1, the incidence of COVID-19 was extremely high in travelers who are mostly asymptomatic for the period under study. Unlike initial studies in Wuhan that reported a 1.3% prevalence in international travelers in the year 2020 [36] and another study in Canada that reports detection of SARS CoV2 in 2.15% of incoming international travelers in the year 2021 [37]. In international travelers leaving the international airport in Mexico City, we found a higher prevalence of 4% with the Delta variant, which increased to 10% during the epidemic peak caused by the Omicron variant. One in ten travelers tested positive, even though most travelers requested an antigen test due to the type of trip and destination, which has been identified as less sensitive than the PCR test. However, since the PCR is more sensitive, it will give us a greater number of positives, which in this case, in apparently healthy people, was from 13% while it was 9.3% with the antigen test. The entire population cannot be tested, but it is remarkable to find an increase of three times the maximum that the SCU had presented at any time during the pandemic period in Mexico. This is the reason why so many people (4 out of 10) have tourism as the reason for their trip, which also explains why the number of children and adolescents occupies about a fifth of the travelers and that 87% are from Mexico or the United States.

The study period for this analysis corresponds to the winter vacation period in Mexico. This is the reason why so many people (4 out of 10) have tourism as the reason for their trip, it also explains why the number of children and adolescents occupies about a fifth of the travelers and that 87% are from Mexico or the United States.

The first point to consider is the low presence of symptoms of COVID-19, 95% of travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or headache as the most common. Screening tests for COVID-19 indicated an incidence of 9.9%, practically one in ten travelers, who did not have any symptoms and those who did reported cough or head
years of age are not vaccinated and they have the highest asymptomatic/symptomatic ratio of all ages, since there were 8.7 asymptomatic for each symptomatic. Even though the incidence of COVID is not the highest according to the age group, the risk of transmission for this group is enormous.

According to nationality, Mexicans represent almost all the symptomatic; as for asymptomatic, Europeans presented this condition in 3.3%, North Americans 4.9% and the rest of the nationalities, including Mexicans, were close to 10% of travelers. This distribution merits characterizing the behavior patterns and the risks to which travelers are exposed while in Mexico. This situation can be associated with the region to which one travels. No symptomatic case was traveling to Europe and only a very low proportion (4%) were asymptomatic. Of the population traveling to North America, 10% tested positive, with asymptomatic cases being 4 times higher. Other international destinations have notably higher levels in both asymptomatic and symptomatic patients.

The results of the study show the rapid escalation of positivity that occurred in Mexico, detected in travelers, from the second half of 2020 to the first semester of 2021, where this ratio was 8.7:1. This points to the absolute need to maintain sanitary measures and carry out good control of those exposed through rapid tests or, preferably, PCR to deal with the pandemic.

CRediT authorship contribution statement

Gustavo Olaiz-Fernández: Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision, Project administration. Félix Jesús Vicuña de Anda: Methodology, Formal analysis, Investigation, Resources, Writing – original draft, Writing – review & editing. Jorge-Baruch Díaz-Ramírez: Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Visualization, Supervision, Project administration. German E. Fajardo Dolci: Term, Conceptualization.

Patricia Bautista-Carbayal: Methodology, Validation, Resources, Data curation. Antonio Humberto Angel-Ambrocio: Methodology, Validation, Resources, Data curation. Miguel Leonardo García-León: Methodology, Validation, Resources, Data curation. Elena Gómez Peña: Methodology, Formal analysis, Investigation, Resources, Writing – original draft, Writing – review & editing. Jorge Alejandro Camacho Morales: Methodology, Validation, Data curation. Rosa María Wong-Chew: Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision, Project administration.

Acknowledgements

The authors would like to thank to Mrs. Josefina Bolado, Head of the Scientific Paper Translation Department, from División de Investigación at Facultad de Medicina UNAM for the diligent proofreading of the English-language version of this manuscript.

References

[1] Karin Leder, Vijaya Sundararajan, Leisa Weldon, Pratika Pandey, Graham Brown, Joseph Torresi, GeoSentinel Surveillance Group, Respiratory tract infections in travelers. A review of the GeoSentinel Surveillance network. Clin Infect Dis. 36 (4): 399-406. https://doi.org/10.1086/346155.
[2] Garg R, Gautam P, Suriyali V, Agarwal R, Bhugra A, Kaur US, et al. Evidence of early community transmission of Omicron (B.1.529) in Delhi: A city with very high seropositivity and past-exposure! medRxiv. (1655):1–13.
[3] Lai S, Li Z, Cleave E, Bondarenko M, Tatem A. Exploring international travel patterns and connected communities for understanding the spreading risk of VOC Omicron. 2021. p. 1–7.
[4] Schermerhorn J, Case A, Graeden E, Kerr J, Robinson-marshall S, Wallace T, et al. Fifteen days in december: capture and analysis of Omicron-related travel restrictions. medRxiv. -1.15. https://doi.org/10.1101/2022.01.26.22269910.
[5] International Organization for Migration (IOM). Global mobility restriction Overview: weekly update. IOM 2022a:1–10.
[6] Garret N, Tapley A, Andriesen J, Betch BS, Leigh H, Ba LB, et al. High rate of asymptomatic carriage associated with variant Strain Omicron. medRxiv. :10-5. https://doi.org/10.1101/2021.12.21.21268130.
[7] Rallí M, Morrone A, Arcangeli A, Ercoli L. Asymptomatic patients as a source of transmission of COVID-19 in homeless shelters. Int J Infect Dis. 102:243-245. http://doi.org/10.1016/j.ijid.2020.12.031.
[8] Ra SH, Lim JS, Kim GU, Kim MJ, Jung J, Kim SH. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax. 76(1):61-65. https://doi.org/10.1136/thoraxjnl-2020-215042.
[9] Tsboi M, Hachiya M, Obitsu H, et al. Epidemiology and risk of COVID-19 among travelers at airport and port quarantine stations across Japan: a nationwide descriptive analysis and an individual-level matched-control study. Clin Infect Dis 2021. Jul https://doi.org/10.1093/cid/ciaa609. PMID: 34318872; PMCID: PMC8406868.
[10] Discllame WE, Warranty ANY, Merchantability OF. COVID-19 travel regulations map* (powered by timatic). Int Air Transp Ass 2021.
[11] Gobierno de México, SRE- Guía del Viajero. Información por destino [Internet]. SRE- Guía del Viajero; 2022. p. 1–3.
[12] Gobierno de México, SRE- Guía del Viajero. Aviso a personas mexicanas por COVID-19 [Internet]. SRE- Guía del Viajero; 2021. p. 1–3.
[13] González Díaz M. Coronavirus en México: como el país se convirtió en un oasis para turistas internacionales en medio de la pandemia (hasta para los que tienen que pasar cuarentena). [Internet]. BBC News Mundo; 2021;
[14] Johansen MA, Quandt TM, Kada S, Pratt JD, Moksnes J, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 4(1):1–8. https://doi.org/10.1001/jamanetworkopen.2020.35057.
[15] Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Chem 41(6):1037–1051. https://doi.org/10.2174/09298671209666666.
[16] Toole AO, Hill V, Pybus OG, Watts A, Bogoch II, Khan K, et al. Tracking the international spread of SARS-CoV-2 lineages B. 1. 1. 7 and B. 1. 351/501V2 [version 1; peer review: 3 approved] network for genomic Surveillance in South Africa (NGS-SA), Danish covid-19 genome consortium (DCGG), communicable. WelcomenoM. Reports. 1 (1).
[17] Antonio-Villa NE, Fernandez-Chirino L, Picaynto-Alatorre J, Mancilla-Galindo J, Kaur-Diez Garcia A, Vazquez-Leon A, et al. Comprehensive evaluation of the impact of Sociodemographic inequalities on adverse Outcomes and excess mortality during the coronavirus disease 2019 (COVID-19) pandemic in Mexico city. Clin Infect Dis. 52(5). https://doi.org/10.1093/cid/ciaa6577.
[18] Weilhalm V, Schmidt F, Zhang F, Dañiliva J, Poston D, Lorenzi JCC, et al. Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants. Elife. 9.1. https://doi.org/10.7554/eLife.61312.
[19] Blman BS, Ramanathan M, Lane AP. COVID-19 vaccines may not prevent nasal and gut infection, and antibody resistance. J Chem Inf Model. 62(2):412-422. https://doi.org/10.1021/acs.jcim.0c01451.
[20] Kandell M, Mohamed MEM, Abd El-Lafeef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol. (December): 1-4. https://doi.org/10.1002/jmv.27915.
[21] Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 375: n2493. https://doi.or
[22] Bleier BS, Ramanathan M, Lane AP. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol Head Neck Surg. 164(2):305-307. https://doi.org/10.1177/0194599820982633.
[23] Polomaticzki Z. EL PEOR A NO EN LA HISTORIA DEL TURISMO CON MIL MILLONES MENOS DE LLEGADAS INTERNACIONALES. Organ Mund del Tur 2020; (34):1-3.
[24] Organización Mundial del Turismo OMT. El turismo crece un 4% en 2021, muy por debajo aún de los niveles prepandémicos. Organ Mund del Tur. (34):1–3.
[25] Sector Resultados de la Universidad de Vigo. Servicio de Proyección Turística, Xunta de Galicia. Julio/23.
[26] Organización Mundial del Turismo OMT. El turismo mundial repunta en El tercer trimestre de 2021, Pero la recuperación Siguiendo siendo Frágil. Organ Mund del Tur. 18(7):1–36.
[27] Salus S. de Laboratorios con reconocimiento por parte del InDRE , para realizar el diagnóstico de COVID 19 , con fines de Vigilancia Epidemiológica [Internet]. Subsecretaria de Prevención y Promoción de la Salud. Dirección General de Epidemiología. Instituto ; 2022. p. 1–8.
[28] Forbes. Alertan sobre pruebas de Covid-19 falsas en aeropuertos y hoteles [Internet]. Forbes México; 2021;
[29] Roo Q, Gobierno E. Mexico combate mercado negro de pruebas de COVID-19 con la Blockchain de Avalanches [Internet]. Centro de Informes; 2021;
[30] Campani J. El negocio de las pruebas falsas de covid: 40 dólares por salir de México [Internet]. El País; 2021;
[31] Rivera-Hernandez M, Fertos NB, Kumar A. The impact of the COVID-19 epidemic on older adults in rural and urban areas in Mexico. J Gerontol B Psychol Sci Soc Sci 76(7): E268-E274. https://doi.org/10.1093/geronb/gzaa227.
[33] Sánchez Talanquer M, González Pier E, Sepúlveda J, Abascal Miguel L, Fieldhouse J, Del Río C, et al. La respuesta de México al Covid-19: Estudio de caso. Inst Glob Heal Sci. :1–131.
[34] Mireles A. Cifra engañosa : el alto índice de letalidad por COVID- México es por el bajo número de pruebas que se realiz [Internet]. Infobae; 2022.
[35] Sanitaria E. México es el país que menos pruebas realiza de Covid-19. Belén: OCDE; Saldívar; 2020.
[36] Luo G, McHenry ML, Letterio JJ. Estimating the prevalence and risk of COVID-19 among international travelers and evacuees of Wuhan through modeling and case reports. PLoS One. 15(6):1–13. https://doi.org/10.1371/journal.pone.0234955.
[37] Lunney M, Ronksley PE, Weaver RG, Barnieh L, Blue N, Avey MT, et al. COVID-19 infection among international travellers: a prospective analysis. BMJ Open. 11(6):1–10. https://doi.org/10.1136/bmjopen-2021-050667.